Onglyza Pancreatic Cancer Health Risk: Persons Taking Onglyza Should Be Aware of the Pancreatic Cancer Health Risk by Onglyza Pancreatic Cancer Lawyer Jason S. Coomer

Recent scientific studies have shown that several diabetes drugs including Onglyza (saxagliptin) may cause an increased risk of pancreatic cancer.  Persons taking Onglyza (saxagliptin) should be aware of the potential danger of pancreatic cancer that they face and discuss the risks of this drug with their health care provider.  If you have been taking the diabetes drug Onglyza (saxagliptin) and have been diagnosed with Pancreatic Cancer or you have lost a loved one from pancreatic cancer that was taking Onglyza (saxagliptin), please report the adverse action to the prescribing medical doctor and FDA as soon as possible.

For persons that have been diagnosed with pancreatic cancer or families that have a loved one that has been diagnosed with pancreatic cancer, please feel free to send an e-mail message to Onglyza Pancreatic Cancer Lawyer Jason Coomer.

Onglyza (Saxagliptin) Is An Oral Diabetes Medication

Onglyza (saxagliptin) is a relatively new oral diabetes drug that is manufactured by Bristol-Myers Squibb and has been aggressively marketed and sold throughout the World.  This agressive marketing and sales has been extremely successful and Onglyza (saxagliptin) sales are one of the fastest growing diabetes drug sales in the World.  

Onglyza (saxagliptin) is an oral diabetes medicine that helps control blood sugar levels. It works by regulating the levels of insulin your body produces after eating.  Onglyza (saxagliptin) is for people with type 2 diabetes. Onglyza (saxagliptin) is sometimes used in combination with other diabetes medications.

In Addition to Onglyza (Saxagliptin) Other Diabetes Drugs in the Incretin Mimetic Class Including Januvia and Janumet May Cause An Increased Risk of Pancreatic Cancer

Diabetes drugs in the incretin mimetic class may cause an increased health risk of pancreatic cancer and pancreatitis.  These incretin diabetes drug include  exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). These drugs work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. They are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.  Many of these incretin diabetes drugs already include a black box warning regarding thyroid cancer risk, but evidence is growing that these drugs may also create an increased risk of pancreatic cancer.

People that are taking incretin diabetes drugs including: Januvia, Janument, Victoza, Byetta, Onglyza, Tradjenta, Bydureon, Oseni, and other diabetes drugs should be aware of the cancer health risks.

If you have been taking a diabetes drug and have been diagnosed with Pancreatic Cancer or you have lost a loved one that was taking a diabetes drug and was diagnosed with pancreatic cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.

Pancreatic Cancer Including Pancreatic Adenocarcinoma and other Forms of Exocrine Pancreas Cancers Are Difficult to Diagnose and Are Often Not Diagnosed Until Late in the Course of the Disease

Pancreatic cancer is the fourth leading cause of cancer death for both men and women and is one of the most deadly of all types of cancer. This year approximately 45,000 Americans will be diagnosed with pancreatic cancer and about 38,000 will die from it.  One of the reasons that pancreatic cancer is so deadly is that it it difficult to diagnose and the diagnosis is often made late in the course of the disease.  Early detection of pancreatic cancer is essential and will greatly improve a person's chances of surviving the disease. As such, people that have taken diabetes drugs, especially those with symptoms of weight loss, dark urine and clay-colored stools, back pain, and jaundice, should seek advice from a qualified medical professional as to if they may have pancreatic cancer and what symptoms they should be aware of to detect any early onset of pancreatic cancer.

Pancreatic Cancer Detection: Understanding and Identifying Symptoms of Pancreatic Cancer Can Be Important In Early Detection and Treatment of Pancreatic Cancer Resulting in Higher Pancreatic Cancer Survival Rates

Symptoms of pancreatic cancer can include: dark urine and clay-colored stools, fatigue and weakness, jaundice (a yellow color in the skin, mucus membranes, or eyes), loss of appetite and weight loss, nausea and vomiting, pain or discomfort in the upper part of the belly or abdomen, back pain, blood clots, diarrhea, and indigestion.

Pancreatic cancer is often not detected early on and is often advanced when it is first found.  As such, ninety-five percent of the people diagnosed with this cancer will not be alive 5 years later.  Some patients have pancreatic cancer that can be surgically removed are cured. However, in more than 80% of patients the tumor has already spread and cannot be completely removed at the time of diagnosis.  In the few cases where pancreatic tumors can be removed by surgery. The standard surgical procedure to remove pancreatic tumors is called a Whipple procedure (pancreatoduodenectomy or pancreaticoduodenectomy). This surgery should be done by an experienced surgeon and at a medical center that performs the procedure often. Some studies suggest that the Whipple procedure is best performed at hospitals that do more than five of these surgeries per year.

When the tumor has not spread out of the pancreas, but cannot be removed, radiation therapy and chemotherapy together may be recommended. When the tumor has spread (metastasized) to other organs such as the liver, chemotherapy alone is usually used. The standard chemotherapy drug is gemcitabine, but other drugs may be used. Gemcitabine can help about 25% of patients.

Patients whose tumor cannot be totally removed, but who have a blockage of the tubes that transport bile (biliary obstruction) must have that blockage relieved. There are two approaches including surgery and placement of a tiny metal tube (biliary stent) during ERCP.

Managing pain and other symptoms is an important part of treating advanced pancreatic cancer. Palliative care tams and hospice can help with pain and symptom management, and provide psychological support for patients and their families during the illness.

Onglyza (Saxagliptin) Pancreatic Cancer Lawyers Handle Dangerous Drug Lawsuits

Texas Dangerous Drug Attorney Jason Coomer commonly works with other lawyers throughout Texas, the United States, and the World including Houston Pancreatic Cancer Lawyers, San Antonio Pancreatic Cancer Lawyers, Dallas Pancreatic Cancer Lawyers, New York Diabetes Drug Pancreatic Cancer Lawyers, Chicago Diabetes Drug Pancreatic Cancer Lawyers, and other Texas Pancreatic Cancer Death Lawyers.  By sharing information and working together, his law firm and other firms throughout World are able to provide better representation for their clients.  

If you have lost a loved one from Pancreatic Cancer or have been diagnosed with Pancreatic Cancer; and have been using Onglyza (Saxagliptin), please report the adverse action to the prescribing medical doctor as soon as possible.  For more information on this topic, please feel free to contact Onglyza Pancreatic Cancer Lawyer Jason Coomer or use our online submission form.

Feel Free to Contact Us with any Questions

Anti-spam Question:


Admitted to Practice in the United States District Court Western District of Texas Capital Area Trial Lawyers Association Logo Austin Bar Association Logo Capital Area Trial Lawyers Association Logo San Antonio Trial Lawyers Association Logo